Peritoneal dialysis fluids.
Journal
Seminars in dialysis
ISSN: 1525-139X
Titre abrégé: Semin Dial
Pays: United States
ID NLM: 8911629
Informations de publication
Date de publication:
24 Feb 2022
24 Feb 2022
Historique:
revised:
04
01
2022
received:
25
10
2021
accepted:
13
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
aheadofprint
Résumé
There have been significant advances in the understanding of peritoneal dialysis (PD) in the last 40 years, and uptake of PD as a modality of kidney replacement therapy is increasing worldwide. PD fluids, therefore, remains the lifeline for patients on this treatment. Developing these fluids to be efficacious in solute clearance and ultrafiltration, with minimal adverse consequences to peritoneal membrane health and systemic effects is a key requirement. Since the first PD fluid produced in 1959, modifications to PD fluids have been made. Nonetheless, the search for that ideal PD fluid remains elusive. Understanding the components of PD fluids is a key aspect of optimizing the successful delivery of PD, allowing for individualized PD prescription. Glucose remains an integral component of PD fluids; however, its deleterious effects continue to be the impetus for the search of an alternative osmotic agent, and icodextrin remains the main alternative. More biocompatible PD fluids have been developed and have shown benefits in preserving residual kidney function. However, high cost and reduced accessibility remain deterrents to its widespread clinical use in many countries. Large-scale clinical trials are necessary and very much awaited to improve the narrow spectrum of PD fluids available for clinical use.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Teschner M, Heidland A, Klassen A, Sebekova K, Bahner U. Georg Ganter-a pioneer of peritoneal dialysis and his tragic academic demise at the hand of the Nazi regime. J Nephrol. May-Jun 2004;17(3):457-460.
Maxwell MH, Rockney RE, Kleeman CR, Twiss MR. Peritoneal dialysis. 1. Technique and applications. Jama. Jun 1959;170(8):917-924. doi:10.1001/jama.1959.03010080025004
Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant. Nov 2001;16(11):2207-2213. doi:10.1093/ndt/16.11.2207
Rippe B, Venturoli D. Optimum electrolyte composition of a dialysis solution. Perit Dial Int. Jun 2008;28(Suppl 3):S131-S136. doi:10.1177/089686080802803s25
Nakayama M, Kawaguchi Y, Yokoyama K, et al. Anti-hypertensive effect of low Na connection (120 mEq/l) solution for CAPD patients. Clin Nephrol. Jun 1994;41(6):357-363.
Nakayama M, Yokoyama K, Kubo H, et al. The effect of ultra-low sodium dialysate in CAPD. A kinetic and clinical analysis. Clin Nephrol. Mar 1996;45(3):188-193.
Davies S, Carlsson O, Simonsen O, et al. The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrol Dial Transplant. May 2009;24(5):1609-1617. doi:10.1093/ndt/gfn668
Rutkowski B, Tam P, van der Sande FM, et al. Low-sodium versus standard-sodium peritoneal dialysis solution in hypertensive patients: a randomized controlled trial. Am J Kidney Dis. May 2016;67(5):753-761. doi:10.1053/j.ajkd.2015.07.031
Davies S, Haraldsson B, Vrtovsnik F, et al. Single-dwell treatment with a low-sodium solution in hypertensive peritoneal dialysis patients. Perit Dial Int. 2020;40(5):446-454. doi:10.1177/0896860820924136
Rao VS, Turner JM, Griffin M, et al. First-in-human experience with peritoneal direct sodium removal using a zero-sodiuM Solution: a new candidate therapy for volume overload. Circulation. Mar 31 2020;141(13):1043-1053. doi:10.1161/CIRCULATIONAHA.119.043062
Haris A, Sherrard DJ, Hercz G. Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int. Sep 2006;70(5):931-937. doi:10.1038/sj.ki.5001666
Weinreich T, Passlick-Deetjen J, Ritz E. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. Am J Kidney Dis. Mar 1995;25(3):452-460. doi:10.1016/0272-6386(95)90108-6
Hutchison AJ, Merchant M, Boulton HF, Hinchcliffe R, Gokal R. Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid. Perit Dial Int. 1993;13(3):219-223. doi:10.1177/089686089301300311
Hutchison AJ, Gokal R. Towards tailored dialysis fluids in CAPD-the role of reduced calcium and magnesium in dialysis fluids. Perit Dial Int. 1992;12(2):199-203. doi:10.1177/089686089201200202
Rotellar C, Kinsel V, Goggins M, Delmez JA. Does low-calcium dialysate accelerate secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients? Perit Dial Int. 1993;13(Suppl 2):S471-S472. doi:10.1177/089686089301300202
Buijsen CG, Struijk DG, Huijgen HJ, Boeschoten EW, Wilmink JM. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients? Perit Dial Int. 1996 Sep-Oct 1996;16(5):497-504. doi:10.1177/089686089601600512
Banalagay E, Bernardini J, Holley J, Chen T, Piraino B. A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis. Adv Perit Dial. 1993;9:280-283.
Parker A, Nolph KD. Magnesium and calcium mass transfer during continuous ambulatory peritoneal dialysis. Trans Am Soc Artif Intern Organs. 1980;26:194-196.
Navarro JF, Mora C, Garcia J. Serum magnesium and parathyroid hormone levels in dialysis patients. Kidney Int. Jun 2000;57(6):2654. doi:10.1046/j.1523-1755.2000.00076.x
Ejaz AA, McShane AP, Gandhi VC, Leehey DJ, Ing TS. Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution. Perit Dial Int. 1995;15(1):61-64. doi:10.1177/089686089501500112
Yang X, Soohoo M, Streja E, et al. Serum magnesium levels and hospitalization and mortality in incident peritoneal dialysis patients: a cohort study. Am J Kidney Dis 10. 2016;68(4):619-627. doi:10.1053/j.ajkd.2016.03.428
Cai K, Luo Q, Dai Z, et al. Hypomagnesemia is associated with increased mortality among peritoneal dialysis patients. PLoS One. 2016;11(3):e0152488. doi:10.1371/journal.pone.0152488
Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. Feb 2012;5(Suppl 1):i52-i61. doi:10.1093/ndtplus/sfr167
Ter Braake AD, Vervloet MG, de Baaij JHF, Hoenderop JGJ. Magnesium to prevent kidney disease-associated vascular calcification: crystal clear? Nephrol Dial Transplant. Dec 2020; doi:10.1093/ndt/gfaa222
Musso CG. Potassium metabolism in patients with chronic kidney disease. Part II: patients on dialysis (stage 5). Int Urol Nephrol. 2004;36(3):469-472. doi:10.1007/s11255-004-6194-y
Szeto CC, Chow KM, Kwan BC, et al. Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication. Am J Kidney Dis. Jul 2005;46(1):128-135. doi:10.1053/j.ajkd.2005.03.015
Amirmokri P, Morgan P, Bastani B. Intra-peritoneal administration of potassium and magnesium: a practical method to supplement these electrolytes in peritoneal dialysis patients. Ren Fail. 2007;29(5):603-605. doi:10.1080/08860220701392215
Yamamoto T, Sakakura T, Yamakawa M, et al. Clinical effects of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis. Nephron. 1992;60(3):324-329. doi:10.1159/000186773
Pedersen FB, Ryttov N, Deleuran P, Dragsholt C, Kildeberg P. Acetate versus lactate in peritoneal dialysis solutions. Nephron. 1985;39(1):55-58. doi:10.1159/000183338
Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20(Suppl 4):S43-S55. doi:10.1177/089686080002004S04
Heimburger O, Mujais S. Buffer transport in peritoneal dialysis. Kidney Int Suppl. Dec 2003;64(88):S37-S42. doi:10.1046/j.1523-1755.2003.08804.x
La Greca G, Biasioli S, Chiaramonte S, et al. Acid-base balance on peritoneal dialysis. Clin Nephrol. Jul 1981;16(1):1-7.
Hernández-Jaras J, García H, Agramunt I. Peritoneal anionic transfers and their relationship with peritoneal transport and acid-base status. Nefrologia. 2002;22(1):42-48.
Uribarri J, Buquing J, Oh MS. Acid-base balance in chronic peritoneal dialysis patients. Kidney Int. Jan 1995;47(1):269-273. doi:10.1038/ki.1995.34
Trinh E, Saiprasertkit N, Bargman JM. Increased serum lactate in peritoneal dialysis patients presenting with intercurrent illness. Perit Dial Int. Sep-Oct 2018;38(5):363-365. doi:10.3747/pdi.2017.00169
Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int. Jul-Aug 1997;17(4):373-378. doi:10.1177/089686089701700413
Bajo MA, del Peso G, Castro MA, et al. Effect of bicarbonate/lactate peritoneal dialysis solutions on human mesothelial cell proliferation ex vivo. Adv Perit Dial. 2001;17:37-41.
Jörres A, Jörres D, Topley N, Gahl GM, Mahiout A. Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions. Nephrol Dial Transplant. 1991;6(7):495-501. doi:10.1093/ndt/6.7.495
Henderson I, Couper I, Lumsden A. Potentially irritant glucose metabolites in unused CAPD fluid. In: Maher J, Winchester J, eds. Frontiers in Peritoneal Dialysis. Springer, Berlin, Heidelberg; 1986:261-264. 10.1007/978-3-662-11784-2_47
Mortier S, Faict D, Gericke M, Lameire N, De Vriese A. Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane. Nephron Exp Nephrol. 2005;101(4):e139-e145. doi:10.1159/000087937
Mortier S, Lameire NH, De Vriese AS. The effects of peritoneal dialysis solutions on peritoneal host defense. Perit Dial Int. Mar-Apr 2004;24(2):123-138. doi:10.1177/089686080402400203
Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int. Nov 1998;54(5):1731-1738. doi:10.1046/j.1523-1755.1998.00167.x
Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int. Apr 1998;53(4):1061-1067. doi:10.1111/j.1523-1755.1998.00849.x
Dratwa M, Wilkie M, Ryckelynck JP, ter Wee PM, Rutherford P, Michel C, Hopwood A, Curtis L, Denys N, Divino Filho JC, Faict D, on Behalf of the Physioneal APD research group. Clinical experience with two physiologic bicarbonate/lactate peritoneal dialysis solutions in automated peritoneal dialysis. Kidney Int Suppl Dec 2003;(88):S105-S113. 10.1046/j.1523-1755.2003.08812.x
Feriani M, Passlick-Deetjen J, Jaeckle-Meyer I, La Greca G, Group S. Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients. Nephrol Dial Transplant. Jan 2004;19(1):195-202. doi:10.1093/ndt/gfg472
Staverman A. The theory of measurement of osmotic pressure. Recueil des Travaux Chimiques des Pays-Bas. 1951;70:344-352. doi:10.1002/recl.19510700409
Perl J, Bargman JM. Peritoneal dialysis: from bench to bedside and bedside to bench. Am J Physiol Renal Physiol 11. 2016;311(5):F999-F1004. doi:10.1152/ajprenal.00012.2016
Gotloib L, Wajsbrot V, Shostak A, Kushnier R. Morphology of the peritoneum: effect of peritoneal dialysis. Perit Dial Int. 1995;15(7 Suppl):S9-S11; discussion. doi:10.1177/089686089501507S01
Honda K, Nitta K, Horita S, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant. Jun 1999;14(6):1541-1549. doi:10.1093/ndt/14.6.1541
Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol. Jul 1998;9(7):1285-1292. doi:10.1681/ASN.V971285
Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol. Sep 2006;17(9):2591-2598. doi:10.1681/ASN.2006030194
Mehrotra R, Ravel V, Streja E, et al. Peritoneal equilibration test and patient outcomes. Clin J Am Soc Nephrol. Nov 2015;10(11):1990-2001. doi:10.2215/CJN.03470315
Heaton A, Johnston DG, Burrin JM, et al. Carbohydrate and lipid metabolism during continuous ambulatory peritoneal dialysis (CAPD): the effect of a single dialysis cycle. Clin Sci (Lond). Nov 1983;65(5):539-545. doi:10.1042/cs0650539
Jiang N, Qian J, Lin A, Lindholm B, Axelsson J, Yao Q. Initiation of glucose-based peritoneal dialysis is associated with increased prevalence of metabolic syndrome in non-diabetic patients with end-stage renal disease. Blood Purif. 2008;26(5):423-428. doi:10.1159/000153248
Selby NM, Fialova J, Burton JO, McIntyre CW. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrol Dial Transplant. Mar 2007;22(3):870-879. doi:10.1093/ndt/gfl654
Turgan C, Feehally J, Bennett S, Davies TJ, Walls J. Accelerated hypertriglyceridemia in patients on continuous ambulatory peritoneal dialysis-a preventable abnormality. Int J Artif Organs. Jul 1981;4(4):158-160. doi:10.1177/039139888100400404
Liao CT, Kao TW, Chou YH, et al. Associations of metabolic syndrome and its components with cardiovascular outcomes among non-diabetic patients undergoing maintenance peritoneal dialysis. Nephrol Dial Transplant. Dec 2011;26(12):4047-4054. doi:10.1093/ndt/gfr175
Wen Y, Guo Q, Yang X, et al. High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. Jan-Feb 2015;35(1):70-77. doi:10.3747/pdi.2013.00083
Pecoits-Filho R, Mujais S, Lindholm B. Future of icodextrin as an osmotic agent in peritoneal dialysis. Kidney Int Suppl. Oct 2002;62(81):S80-S87. doi:10.1046/j.1523-1755.62.s81.11.x
Silver SA, Harel Z, Perl J. Practical considerations when prescribing icodextrin: a narrative review. Am J Nephrol. 2014;39(6):515-527. doi:10.1159/000363417
Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol. Sep 2003;14(9):2338-2344. doi:10.1097/01.asn.0000083904.12234.27
Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int. Aug 1994;46(2):496-503. doi:10.1038/ki.1994.300
Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int. Apr 2003;63(4):1556-1563. doi:10.1046/j.1523-1755.2003.00887.x
Wolfson M, Piraino B, Hamburger RJ, Morton AR, Group IS. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis. Nov 2002;40(5):1055-1065. doi:10.1053/ajkd.2002.36344
Qi H, Xu C, Yan H, Ma J. Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials. Perit Dial Int. Mar-Apr 2011;31(2):179-188. doi:10.3747/pdi.2009.00264
Cho Y, Johnson DW, Badve S, Craig JC, Strippoli GF, Wiggins KJ. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant. Jul 2013;28(7):1899-1907. doi:10.1093/ndt/gft050
Htay H, Johnson DW, Wiggins KJ, et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev. 2018;10(10):CD007554 doi:10.1002/14651858.CD007554.pub3
Goossen K, Becker M, Marshall MR, et al. Icodextrin versus glucose solutions for the once-daily long dwell in peritoneal dialysis: an enriched systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis. 2020;75(6):830-846. doi:10.1053/j.ajkd.2019.10.004
Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant. Jun 2000;15(6):862-866. doi:10.1093/ndt/15.6.862
Paniagua R, Ventura MD, Ávila-Díaz M, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009 Jul-Aug. 2009;29(4):422-432. doi:10.1177/089686080902900409
Paniagua R, Orihuela O, Ventura MD, et al. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney Int Suppl. Apr 2008;73(108):S125-S130. doi:10.1038/sj.ki.5002613
Akonur A, Sloand J, Davis I, Leypoldt J. Icodextrin simplifies PD therapy by equalizing UF and sodium removal among patient transport types during long dwells: a modeling study. Perit Dial Int. Jan-Feb 2016;36(1):79-84. doi:10.3747/pdi.2013.00081
Fourtounas C, Hardalias A, Dousdampanis P, Papachristopoulos B, Savidaki E, Vlachojannis JG. Sodium removal in peritoneal dialysis: the role of icodextrin and peritoneal dialysis modalities. Adv Perit Dial. 2008;24:27-31.
Fourtounas C, Dousdampanis P, Hardalias A, Vlachojannis JG. Sodium removal and peritoneal dialysis modalities: no differences with optimal prescription of icodextrin. Artif Organs. Jul 2013;37(7):E107-E113. doi:10.1111/aor.12061
Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis. Apr 2002;39(4):862-871. doi:10.1053/ajkd.2002.32009
He Q, Zhang W, Chen J. A meta-analysis of icodextrin versus glucose containing peritoneal dialysis in metabolic management of peritoneal dialysis patients. Ren Fail. 2011;33(10):943-948. doi:10.3109/0886022X.2011.615965
Chang TI, Ryu DR, Yoo TH, et al. Effect of icodextrin solution on the preservation of residual renal function in peritoneal dialysis patients: a randomized controlled study. Medicine (Baltimore). Mar 2016;95(13):e2991. doi:10.1097/MD.0000000000002991
Sniderman AD, Sloand JA, Li PK, Story K, Bargman JM. Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials. J Clin Lipidol. Jul-Aug 2014;8(4):441-447. doi:10.1016/j.jacl.2014.03.007
Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int. Jan-Feb 1997;17(1):84-87. doi:10.1177/089686089701700118
Johnson DW, Arndt M, O'Shea A, Watt R, Hamilton J, Vincent K. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol. Dec 2001;2(1):2 doi:10.1186/1471-2369-2-2
Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis. Nephrol Dial Transplant. May 2012;27(5):2044-2050. doi:10.1093/ndt/gfr580
Sav T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C. Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. Jul-Aug 2009;29(4):443-449. doi:10.1177/089686080902900411
Dousdampanis P, Trigka K, Chu M, et al. Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature. Int Urol Nephrol. Mar 2011;43(1):203-209. doi:10.1007/s11255-010-9716-9
Dallas F, Jenkins SB, Wilkie ME. Enhanced ultrafiltration using 7.5% icodextrin/1.36% glucose combination dialysate: a pilot study. Perit Dial Int. Nov-Dec 2004;24(6):542-546. doi:10.1177/089686080402400613
Diaz-Buxo JA, Passlick-Deetjen J, Gotloib L. Potential hazards of polyglucose. ASAIO J. Nov-Dec 2001;47(6):602-607. doi:10.1097/00002480-200111000-00006
Seow YY, Iles-Smith H, Hirst H, Gokal R. Icodextrin-associated peritonitis among CAPD patients. Nephrol Dial Transplant. Sep 2003;18(9):1951-1952. doi:10.1093/ndt/gfg305
Gokal R, Moberly J, Lindholm B, Mujais S. Metabolic and laboratory effects of icodextrin. Kidney Int Suppl. Oct 2002;62(81):S62-S71. doi:10.1046/j.1523-1755.62.s81.9.x
Brown EA, Blake PG, Boudville N, et al. International Society for Peritoneal Dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis. Perit Dial Int. 2020;40(3):244-253. doi:10.1177/0896860819895364
van Biesen W, Heimburger O, Krediet R, van Biesen W, Rippe B, la Milia V, Covic A, Vanholder R, for the ERBP working group on peritoneal dialysis. Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. Nephrol Dial Transplant. Jul 2010;25(7):2052-2062. doi:10.1093/ndt/gfq100
Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. Nephron. 1986;42(2):133-140. doi:10.1159/000183652
Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. Sep 1993;329(14):1001-1006. doi:10.1056/NEJM199309303291404
Zha Y, Qian Q. Protein nutrition and malnutrition in CKD and ESRD. Nutrients. Feb 2017;9(3): doi:10.3390/nu9030208
Lindholm B, Park MS, Bergström J. Supplemented dialysis: amino acid-based solutions in peritoneal dialysis. Contrib Nephrol. 1993;103:168-182. doi:10.1159/000422285
Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int. Apr 1995;47(4):1148-1157. doi:10.1038/ki.1995.164
Jones M, Hagen T, Boyle CA, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis. Nov 1998;32(5):761-769. doi:10.1016/s0272-6386(98)70131-3
Tjiong HL, van den Berg JW, Wattimena JL, et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol. May 2005;16(5):1486-1493. doi:10.1681/ASN.2004050402
Grzegorzewska AE, Mariak I, Dobrowolska-Zachwieja A, Szajdak L. Effects of amino acid dialysis solution on the nutrition of continuous ambulatory peritoneal dialysis patients. Perit Dial Int. Sep-Oct 1999;19(5):462-470. doi:10.1177/089686089901900510
Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown EA. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. May-Jun 1997;17(3):279-286. doi:10.1177/089686089701700312
Asola M, Virtanen K, Någren K, et al. Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle. Kidney Int Suppl. Apr 2008;73(108):S131-S136. doi:10.1038/sj.ki.5002614
Daniels FH, Leonard EF, Cortell S. Glucose and glycerol compared as osmotic agents for peritoneal dialysis. Kidney Int. Jan 1984;25(1):20-25. doi:10.1038/ki.1984.3
Smit W, de Waart DR, Struijk DG, Krediet RT. Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis. Perit Dial Int. Sep-Oct 2000;20(5):557-565. doi:10.1177/089686080002000511
Cho Y, Johnson DW, Badve SV, Craig JC, Strippoli GF, Wiggins KJ. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int. Nov 2013;84(5):969-979. doi:10.1038/ki.2013.190
Seo EY, An SH, Cho JH, et al. Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials. Perit Dial Int. Nov-Dec 2014;34(7):724-731. doi:10.3747/pdi.2012.00331
Wang J, Zhu N, Yuan W. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis. Nephron. 2015;129(3):155-163. doi:10.1159/000368235
Yohanna S, Alkatheeri AM, Brimble SK, et al. Effect of neutral-pH, low-glucose degradation product peritoneal dialysis solutions on residual renal function, urine volume, and ultrafiltration: a systematic review and meta-analysis. Clin J Am Soc Nephrol. Aug 2015;10(8):1380-1388. doi:10.2215/CJN.05410514
Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol. Jun 2012;23(6):1097-1107. doi:10.1681/ASN.2011121201
Kooman JP, Cornelis T, van der Sande FM, Leunissen KM. Is the effect of low-GDP solutions on residual renal function mediated by fluid state? An enigmatic question which still needs to be solved. Perit Dial Int. May-Jun 2016;36(3):239-242. doi:10.3747/pdi.2015.00149
Johnson DW, Brown FG, Clarke M, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Perit Dial Int. Sep-Oct 2012;32(5):497-506. doi:10.3747/pdi.2012.00052
Farhat K, Douma CE, Ferrantelli E, Ter Wee PM, Beelen RHJ, van Ittersum FJ. Effects of conversion to a bicarbonate/lactate-buffered, neutral-pH, low-GDP PD regimen in prevalent PD: a 2-year randomized clinical trial. Perit Dial Int. May-Jun 2017;37(3):273-282. doi:10.3747/pdi.2015.00031
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MWY, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D, on behalf of the balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant. Dec 2012;27(12):4445-4453. doi:10.1093/ndt/gfs314
Rippe B, Simonsen O, Heimbürger O, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int. Jan 2001;59(1):348-357. doi:10.1046/j.1523-1755.2001.00497.x
Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant. Aug 2004;19(8):2101-2106. doi:10.1093/ndt/gfh326
Lai KN, Lam MF, Leung JC, et al. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Perit Dial Int. May-Jun 2012;32(3):280-291. doi:10.3747/pdi.2010.00176
Cho Y, Johnson DW, Craig JC, Strippoli GF, Badve SV, Wiggins KJ. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev. Mar 2014;(3):CD007554. doi:10.1002/14651858.CD007554.pub2
Sevinc Ok E, Asci G, Kircelli F, et al. Relationship between glucose exposure via peritoneal dialysis solutions and coronary artery calcification in non-diabetic peritoneal dialysis patients. Int Urol Nephrol. Dec 2012;44(6):1847-1853. doi:10.1007/s11255-012-0138-8
Uiterwijk H, Franssen CFM, Kuipers J, Westerhuis R, Nauta FL. Glucose exposure in peritoneal dialysis is a significant factor predicting peritonitis. Am J Nephrol. 2020;51(3):237-243. doi:10.1159/000506324
Yung S, Lui SL, Ng CK, et al. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers. Perit Dial Int. Mar-Apr 2015;35(2):147-158. doi:10.3747/pdi.2014.00125
Li PK, Culleton BF, Ariza A, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol. Nov 2013;24(11):1889-1900. doi:10.1681/ASN.2012100987
Bonomini M, Di Liberato L, Zammit V, Arduini A. Current opinion on usage of L-carnitine in end-stage renal disease patients on peritoneal dialysis. Molecules. Sep 2019;24(19). doi:10.3390/molecules24193449
Schreiber B. Levocarnitine and dialysis: a review. Nutr Clin Pract. Apr 2005;20(2):218-243. doi:10.1177/0115426505020002218
Warady BA, Borum P, Stall C, Millspaugh J, Taggart E, Lum G. Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol. 1990;10(2):109-114. doi:10.1159/000168064
Koşan C, Sever L, Arisoy N, Calişkan S, Kasapçopur O. Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatr Nephrol. Nov 2003;18(11):1184-1188. doi:10.1007/s00467-003-1302-2
Verrina E, Caruso U, Calevo MG, on behalf of the Italian Registry of Pediatric Chronic Dialysis, Emma F, Sorino P, de Palo T, Lavoratti G, Turrini Dertenois L, Cassanello M, Cerone R, Perfumo F Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr Nephrol. May 2007;22(5):727-733. doi:10.1007/s00467-006-0408-8
Lilien MR, Duran M, Quak JM, Frankhuisen JJ, Schröder CH. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol. Nov 2000;15(1-2):17-20. doi:10.1007/s004670000423
Sotirakopoulos N, Athanasiou G, Tsitsios T, Mavromatidis K. The influence of L-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD. Ren Fail. Jul 2002;24(4):505-510. doi:10.1081/jdi-120006777
Bonomini M, Di Liberato L, Del Rosso G, et al. Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial. Am J Kidney Dis. Nov 2013;62(5):929-938. doi:10.1053/j.ajkd.2013.04.007
Nakayama M, Zhu WJ, Watanabe K, et al. Dissolved molecular hydrogen H. BMC Nephrol. Oct 2017;18(1):327. doi:10.1186/s12882-017-0741-0
Nakayama M, Watanabe K, Hayashi Y, et al. Translational research of peritoneal dialysis solution with dissolved molecular hydrogen. Contrib Nephrol. 2018;196:162-170. doi:10.1159/000485717
Du C, Mendelson AA, Guan Q, et al. Hyperbranched polyglycerol is superior to glucose for long-term preservation of peritoneal membrane in a rat model of chronic peritoneal dialysis. J Transl Med. 2016;14(1):338. doi:10.1186/s12967-016-1098-z
Leypoldt JK, Hoff CM, Piscopo D, Carr SN, Svatek JM, Holmes CJ. Ultrafiltration characteristics of glucose polymers with low polydispersity. Perit Dial Int. Mar-Apr 2013;33(2):124-131. doi:10.3747/pdi.2012.00009
Leypoldt JK, Hoff CM, Akonur A, Holmes CJ. Low-polydispersity glucose polymers as osmotic agents for peritoneal dialysis. Perit Dial Int. Jul-Aug 2015;35(4):428-435. doi:10.3747/pdi.2013.00232